Literature DB >> 32057801

Modulating inhibitory response control through potentiation of GluN2D subunit-containing NMDA receptors.

Patrick M Callahan1, Alvin V Terry1, Frederick R Nelson2, Robert A Volkmann2, A B Vinod3, Mohd Zainuddin3, Frank S Menniti4.   

Abstract

NMDA receptors containing GluN2D subunits are expressed in the subthalamic nucleus and external globus pallidus, key nuclei of the indirect and hyperdirect pathways of the basal ganglia. This circuitry integrates cortical input with dopaminergic signaling to select advantageous behaviors among available choices. In the experiments described here, we characterized the effects of PTC-174, a novel positive allosteric modulator (PAM) of GluN2D subunit-containing NMDA receptors, on response control regulated by this circuitry. The indirect pathway suppresses less advantageous behavioral choices, a manifestation of which is suppression of locomotor activity in rats. Systemic administration of PTC-174 produced a dose-dependent reduction in activity in rats placed in a novel open field or administered the stimulants MK-801 or amphetamine. The hyperdirect pathway controls release of decisions from the basal ganglia to the cortex to optimize choice processing. Such response control was modeled in rats as premature responding in the 5-choice serial reaction time (5-CSRT) task. PTC-174 produced a dose-dependent reduction in premature responding in this task. These data suggest that potentiation of GluN2D receptor activity by PTC-174 facilitates the complex basal ganglia information processing that underlies response control. The behavioral effects occurred at estimated free PTC-174 brain concentrations predicted to induce 10-50% increases in GluN2D activity. The present findings suggest the potential of GluN2D PAMs to modulate basal ganglia function and to treat neurological disorders related to dysfunctional response control.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Basal ganglia; Executive function; GluN2D positive allosteric modulators; Inhibitory response control; NMDA receptors

Mesh:

Substances:

Year:  2020        PMID: 32057801      PMCID: PMC7293930          DOI: 10.1016/j.neuropharm.2020.107994

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  44 in total

Review 1.  Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway.

Authors:  Atsushi Nambu; Hironobu Tokuno; Masahiko Takada
Journal:  Neurosci Res       Date:  2002-06       Impact factor: 3.304

2.  A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors.

Authors:  Praseeda Mullasseril; Kasper B Hansen; Katie M Vance; Kevin K Ogden; Hongjie Yuan; Natalie L Kurtkaya; Rose Santangelo; Anna G Orr; Phuong Le; Kimberly M Vellano; Dennis C Liotta; Stephen F Traynelis
Journal:  Nat Commun       Date:  2010-10-05       Impact factor: 14.919

3.  Control of basal ganglia output by direct and indirect pathway projection neurons.

Authors:  Benjamin S Freeze; Alexxai V Kravitz; Nora Hammack; Joshua D Berke; Anatol C Kreitzer
Journal:  J Neurosci       Date:  2013-11-20       Impact factor: 6.167

Review 4.  Reassessing models of basal ganglia function and dysfunction.

Authors:  Alexandra B Nelson; Anatol C Kreitzer
Journal:  Annu Rev Neurosci       Date:  2014       Impact factor: 12.449

5.  Identification of subunits contributing to synaptic and extrasynaptic NMDA receptors in Golgi cells of the rat cerebellum.

Authors:  C Misra; S G Brickley; M Farrant; S G Cull-Candy
Journal:  J Physiol       Date:  2000-04-01       Impact factor: 5.182

6.  GluN2D-Containing N-methyl-d-Aspartate Receptors Mediate Synaptic Transmission in Hippocampal Interneurons and Regulate Interneuron Activity.

Authors:  Riley E Perszyk; John O DiRaddo; Katie L Strong; Chian-Ming Low; Kevin K Ogden; Alpa Khatri; Geoffrey A Vargish; Kenneth A Pelkey; Ludovic Tricoire; Dennis C Liotta; Yoland Smith; Chris J McBain; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2016-09-13       Impact factor: 4.436

7.  Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574.

Authors:  Christopher L Shaffer; Raymond S Hurst; Renato J Scialis; Sarah M Osgood; Dianne K Bryce; William E Hoffmann; John T Lazzaro; Ashley N Hanks; Susan Lotarski; Mark L Weber; JianHua Liu; Frank S Menniti; Christopher J Schmidt; Mihály Hajós
Journal:  J Pharmacol Exp Ther       Date:  2013-07-30       Impact factor: 4.030

8.  Opposing role of NMDA receptor GluN2B and GluN2D in somatosensory development and maturation.

Authors:  Miwako Yamasaki; Rieko Okada; Chihiro Takasaki; Shima Toki; Masahiro Fukaya; Rie Natsume; Kenji Sakimura; Masayoshi Mishina; Tetsuo Shirakawa; Masahiko Watanabe
Journal:  J Neurosci       Date:  2014-08-27       Impact factor: 6.167

9.  NMDA Receptors in the Central Nervous System.

Authors:  Kasper B Hansen; Feng Yi; Riley E Perszyk; Frank S Menniti; Stephen F Traynelis
Journal:  Methods Mol Biol       Date:  2017

10.  Essential role of NMDA receptor channel ε4 subunit (GluN2D) in the effects of phencyclidine, but not methamphetamine.

Authors:  Yoko Hagino; Shinya Kasai; Wenhua Han; Hideko Yamamoto; Toshitaka Nabeshima; Masayoshi Mishina; Kazutaka Ikeda
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

View more
  2 in total

1.  Biophysical and Architectural Mechanisms of Subthalamic Theta under Response Conflict.

Authors:  Prannath Moolchand; Stephanie R Jones; Michael J Frank
Journal:  J Neurosci       Date:  2022-04-27       Impact factor: 6.709

Review 2.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.